MedPath

Refinement and Clinical Evaluation of the H-Man for Arm Rehabilitation After Stroke

Not Applicable
Completed
Conditions
Stroke
Interventions
Other: Additional Conventional Therapy
Device: H-Man
Registration Number
NCT02188628
Lead Sponsor
Tan Tock Seng Hospital
Brief Summary

Locally, stroke remains the 4th cause of death, causing 8.4% of deaths annually in Singapore, and a leading cause of neurological disability worldwide. Nearly 40% of the stroke survivors will require specialized rehabilitation. In recent years, robot-aided therapy has been proposed as a means of complementing traditional therapy to alleviate the burden on therapists and on the healthcare system. For shoulder/elbow rehabilitation, dozens of robots have been proposed in the literature but only half a dozen have been commercialized and typically none are seen in local clinics, due to exceedingly high costs. A novel, compact, inexpensive robotic interface, named 'H-Man', was recently designed and developed at NTU for experiments in motor control neuroscience. The H-man can generate computer-controlled force fields to assist or resist a subject's motion and is potentially an optimal trade-off between clinical efficacy and robotic complexity. A first prototype of the H-Man is available at NTU.The primary aim of this proposed project is to assess to what extent the investigators H-Man is suitable for rehabilitation purposes using a feasibility pilot clinical trial design involving stroke survivors. The investigators believe that H-Man can be used for neuro-rehabilitation of stroke patients with hemiparetic weakness, motor incoordination and motor ataxia of the upper limbs.In close cooperation between clinicians at the TTSH and NTU engineers, a portable version of the H-Man will be developed which will be tested in a 12 subject Pilot study, refined and then used in a 44 subject Randomized Controlled Trial (RCT) study. At the same time, the feasibility of H-Man integration for a pared down home use model will be assessed in 4 subjects.

The investigators primary hypothesis is that sub-acute/chronic patients will exhibit clinically significant decreases of impairment when training with the H-Man combined with standard arm therapy on robot-measured scales and standardized clinical scales, at the level of elbow/shoulder after 18 sessions of training on the H-Man.

Detailed Description

As above

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
44
Inclusion Criteria
  • First ever clinical stroke (ischaemic or haemorrhagic) confirmed on brain imaging
  • Duration post stroke: 3 months to 24 months
  • Age 21 to 85 years
  • Hemiplegic pattern of arm motor impairment with Shoulder abduction MRC motor power >/= 3/5 and elbow flexion MRC motor power >/= 3/5
  • Affected upper limb Fugl Myer Motor Assessment (FMMA) scale 20-50
  • And / or associated motor incoordination or motor ataxia
Exclusion Criteria
  • Non stroke related causes of arm motor impairment
  • Medical conditions incompatible with research participation: uncontrolled medical illnesses (hypertension or diabetes, heart failure, asthma, depression, end stage renal failure, terminal malignancy), life expectancy <6 months, unhealed fractures or severe arm pain (visual analogue scale VAS > 5/10, pregnancy
  • Inability to tolerate sitting for 90 minutes.
  • Local factors which preclude robotic interfacing or may be worsened by intensive arm therapy: spasticity of Modified Ashworth Scale grades 3-4, skin wounds, shoulder pain VAS >5/10, active fractures or arthritis or fixed flexion contractures of shoulder, elbow, wrist or fingers incompatible with interface with the H-man robot.
  • Severe sensory impairment of affected limb
  • Severe visual impairment, hemispatial neglect or homonymous hemianopia
  • Cognitive impairments or uncontrolled behaviour. (Folstein mini mental state exam MMSE <26/28)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Additional Conventional TherapyAdditional Conventional TherapyRepetitive goals based arm therapy
H-ManH-ManH-Man is a novel, portable, inexpensive end-effector upper limb robot.
Primary Outcome Measures
NameTimeMethod
Change from Baseline in Fugl Meyer Assessment of Motor Recovery0, 3, 6, 12 and 24 weeks after start of intervention

As above

Secondary Outcome Measures
NameTimeMethod
Change from Baseline in Action Research Arm Test0, 3, 6, 12 and 24 weeks after start of intervention

As above

Trial Locations

Locations (1)

Tan Tock Seng Rehabilitation Centre

🇸🇬

Singapore, Singapore

© Copyright 2025. All Rights Reserved by MedPath